A preclinical evaluation of the MEK inhibitor refametinib in HER2-positive breast cancer cell lines including those with acquired resistance to trastuzumab or lapatinib

PURPOSE: The MEK/MAPK pathway is commonly activated in HER2-positive breast cancer, but little investigation of targeting this pathway has been undertaken. Here we present the results of an in vitro preclinical evaluation of refametinib, an allosteric MEK1/2 inhibitor, in HER2-positive breast cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Shea, John, Cremona, Mattia, Morgan, Clare, Milewska, Malgorzata, Holmes, Frankie, Espina, Virginia, Liotta, Lance, O’Shaughnessy, Joyce, Toomey, Sinead, Madden, Stephen F., Carr, Aoife, Elster, Naomi, Hennessy, Bryan T., Eustace, Alex J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5689598/
https://www.ncbi.nlm.nih.gov/pubmed/29156708
http://dx.doi.org/10.18632/oncotarget.19461

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5689598/
https://www.ncbi.nlm.nih.gov/pubmed/29156708
http://dx.doi.org/10.18632/oncotarget.19461

Ejemplares similares